Skip to main content
. 2017 Sep 26;6(3):174–182. doi: 10.22088/acadpub.BUMS.6.3.174

Table 3.

Clinical and laboratory data of the study group, divided into twosubgroups: LAR (local allergic rhinitis) and NAR (non allergic rhinitis).

LAR patients NAR patients
Subjects (N) 16 10
Groups of rhinitis symptoms severity (N)
Group 1 2 4
Group 2 8 2
Group 3 2 2
Group 4 4 2
Family history of allergy (N):
Yes 10 6
No 6 2
Nasal lavage fluid IgE 6.005+/- 0.3947 2.883+/- 0.1279
NARES cases (N) 2 2
Adenoid hypertrophy≥ 2nd grade (N) 10 6
Response to pregress rhinitis therapy (good response, N)
Nasal steroid - -
Antihistamine 2 2
Montelukast - 2
Nasal steroid+ Antihistamine 4 2
Antihistamine+ Montelukast 2 -
Montelukast+ Nasal steroid - -
Nasal steroid+ Antihistamine+ Montelukast 2 -
Never done therapy 4 2